 This is an open-label, uncontrolled, non-randomised multi-centre trial in which 3 parallel groups will be enrolled. The trial includes three active treatment groups. To be eligible for inclusion in this trial, subjects must have at least 15 clinically typical, visible, and discrete actinic keratosis AKs on the face, scalp or on the arm within a contiguous area of approximately 250 cm2 of sun-damaged skin. 